Abstract: A battery module and a short protection method thereof are provided. The battery module has a battery cell pack and a control circuit. The method includes: detecting a temperature of the battery cell pack as a battery cell temperature through the control circuit; determining whether the battery cell temperature shows a downward trend when the battery cell temperature is higher than a first predetermined temperature value; and deactivating the battery module when the battery cell temperature does not show the downward trend.

Abstract: The disclosure provides a power management method. The power management method is applicable to an electronic device. The electronic device is electrically coupled to an adapter, and includes a system and a battery. The adapter has a feed power. The battery has a discharge power. The power management method of the disclosure includes: reading a power value of the battery; determining a state of the system; and discharging power to the system, when the system is in a power-on state and the power value is greater than a charging stopping value, by using the battery, and controlling, according to the discharge power and the feed power, the adapter to selectively supply power to the system. The disclosure further provides an electronic device using the power management method.

Abstract: The present invention provides a method for assessing the risk of drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative in a subject in need of such an assessment, comprising the step of detecting the presence of HLA-B alleles in the sample obtained from the subject, wherein the presence of the allele indicates that the subject has an increased risk of developing drug hypersensitivity reaction caused by the antiepileptic drug with the sulfonamide derivative. The present invention also provides a method for treating or reducing the incidence of such drug hypersensitivity reaction. Also provided are a test kit for assessing the risk of a patient developing drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative, comprising a reagent for determining specific HLA alleles, and use of the test kit in assessing the risk of a patient developing drug hypersensitivity reaction caused by an antiepileptic drug with a sulfonamide derivative.

Abstract: The present invention relates to methods for treating dermatitis and the use of a ?-1 adrenoceptor antagonist in manufacturing a pharmaceutical composition for treating dermatitis. The methods comprise the step of administering the pharmaceutical composition comprising a therapeutically effective amount of ?-1 adrenoceptor antagonist to a subject in need thereof.

Abstract: The present invention relates to the use of ?-1 adrenergic receptor antagonist to prepare compositions for reducing or preventing damage to normal epithelial cells induced by epidermal growth factor receptor inhibitor (EGFRI) and inhibiting cancer cells, by administering a composition containing a ?-1 adrenergic receptor antagonist to reduce damage to normal epithelial cells induced by the EGFRI. The composition comprising ?-1 adrenergic receptor antagonist is administered to reduce damage to normal epithelial cells induced by the EGFRI. The composition comprising ?-1 adrenergic receptor antagonist can be administered together with an epidermal growth factor receptor inhibitor to synergistically inhibit cancer cells.

Abstract: A method for assessing the risk of cutaneous adverse drug reactions (CADRs) caused by an epidermal growth factor receptor inhibitor is provided, wherein the CADRs comprises but not limited to: maculopapular eruption (MPE), erythema multiforme (EM), Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS). Also provided is a detection kit for assessing the risk of developing CADRs in patients, said kit comprising a reagent for determining specific HLA alleles and a use of the detection kit in assessing the risk of developing CADR in a patient.

Abstract: A method for assessing the risk of severe cutaneous adverse drug reactions (SCARs) induced by disease-modifying antirheumatic drugs is provided, wherein the severe cutaneous adverse drug reactions comprises but not being limited to: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS). Also provided is a detection kit for assessing the risk of developing cutaneous adverse drug reactions in a subject, said kit comprising a reagent for determining specific HLA alleles and a use of the detection kit in assessing the risk of developing cutaneous adverse drug reactions in a subject.

Abstract: Methods for assessing the risk of developing adverse drug reaction in a subject in need of such assessment are provided, comprising the step of detecting the presence of an HLA-B allele in a sample obtained from the subject, wherein the presence of allele is indicative of the subject having an increased risk of developing the adverse drug reaction. Also provided are methods of treating or reducing the incidence of the adverse drug reaction.

Abstract: Methods for treating a wound or promote wound healing are provided, comprising the step of administering a composition including an effective amount of ?-1 adrenergic receptor antagonist to a subject in need thereof. Also provided is apparatus for wound healing, comprising a dressing and a composition including an effective amount of ?-1 adrenergic receptor antagonist.

Abstract: Methods for treating a wound or promote wound healing are provided, comprising the step of administering a composition including an effective amount of ?-1 adrenergic receptor antagonist to a subject in need thereof. Also provided is apparatus for wound healing, comprising a dressing and a composition including an effective amount of ?-1 adrenergic receptor antagonist.

Abstract: Provided is a method for evaluating the risk of drug hypersensitivity reaction induced by antibiotics sulfamethoxazole and/or trimethoprim. The drug hypersensitivity reaction comprises: maculopapular eruption, fixed drug eruption, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms. A specific HLA genotype is associated with the drug hypersensitivity reaction induced by the antibiotics sulfamethoxazole and/or trimethoprim.

Abstract: A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including rs1057910 (CYP2C9*3) and rs3758581 on CYP2C19), and HLA alleles (including HLA-B*1502, HLA-B*1301, and HLA-B*5101) can predict adverse reactions caused by phenytoin or fosphenytoin. Accordingly, the present invention provides a kit to assess the risk of a patient for developing adverse reactions in response to phenytoin-related drugs, which comprises the determination of the presence of a specific allele selected from the group consisting of rs1057910 (CYP2C9*3), rs3758581 on CYP2C19, HLA-B*1502, HLA-B*1301, and HLA-B*5101, wherein the presence of at least one allele is indicative of a risk for the adverse drug reactions.

Abstract: A method for assessing the risk of cutaneous adverse drug reactions induced by an anti-epileptic drug Lamotrigine is provided, wherein the cutaneous adverse drug reactions include but are not limited to: maculopapular eruption (MPE), fixed drug eruption (FDE), Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS). Further provided is a detection reagent for assessing the risk of a patient developing the cutaneous adverse drug reactions induced by the anti-epileptic drug Lamotrigine, comprising agents for measuring a particular HLA allele and the use thereof.

Abstract: Methods for treating a wound or promote wound healing are provided, comprising the step of administering a composition including an effective amount of ?-1 adrenergic receptor antagonist to a subject in need thereof. Also provided is apparatus for wound healing, comprising a dressing and a composition including an effective amount of ?-1 adrenergic receptor antagonist.

Abstract: Provided is a method for evaluating the risk of drug hypersensitivity reaction induced by antibiotics sulfamethoxazole and/or trimethoprim. The drug hypersensitivity reaction comprises: maculopapular eruption, fixed drug eruption, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms. A specific HLA genotype is associated with the drug hypersensitivity reaction induced by the antibiotics sulfamethoxazole and/or trimethoprim.

Abstract: Disclosed are a method and an identification kit for identifying a causative drug for a drug hypersensitivity reaction, including: first, biological sample lymphocytes and a suspected drug or the metabolites thereof are co-cultured in vitro to form reactants, and then the expression levels of the granulysin protein, polypeptide or mRNA in the reactants are detected and compared with the control values, then the degree that the suspected drug or the metabolites thereof activate lymphocytes can be identified, thus identifying the causative drug that initiates the drug hypersensitivity reaction. The causative drug comprises Western medicine, traditional Chinese medicine, a vaccine and an antigen molecule that can cause T-cell activation.

Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

Abstract: A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including rs1057910 (CYP2C9*3) and rs3758581 on CYP2C19), and HLA alleles (including HLA-B*1502, HLA-B*1301, and HLA-B*5101) can predict adverse reactions caused by phenytoin or fosphenytoin. Accordingly, the present invention provides a kit to assess the risk of a patient for developing adverse reactions in response to phenytoin-related drugs, which comprises the determination of the presence of a specific allele selected from the group consisting of rs1057910 (CYP2C9*3), rs3758581 on CYP2C19, HLA-B*1502, HLA-B*1301, and HLA-B*5101, wherein the presence of at least one allele is indicative of a risk for the adverse drug reactions.

Abstract: The invention pertains to topical pharmaceutical formulations of berberine and its biologically equivalent analogs, such as palmatine and coptisine, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than 0.1%. The invention also pertains to methods of treating rosacea and other red face related skin disorders, such as steroid-induced rosacea-like dermatitis, comprising the administration of topical pharmaceutical formulations that contain berberine or its biologically equivalent analogs, such as palmatine.

Abstract: A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including rs1057910 (CYP2C9*3) and rs3758581 on CYP2C19), and HLA alleles (including HLA-B*1502, HLA-B*1301, and HLA-B*5101) can predict adverse reactions caused by phenytoin or fosphenytoin. Accordingly, the present invention provides a kit to assess the risk of a patient for developing adverse reactions in response to phenytoin-related drugs, which comprises the determination of the presence of a specific allele selected from the group consisting of rs1057910 (CYP2C9*3), rs3758581 on CYP2C19, HLA-B*1502, HLA-B*1301, and HLA-B*5101, wherein the presence of at least one allele is indicative of a risk for the adverse drug reactions.